Science names HIV prevention trial as '2011 Breakthrough of the Year'

"The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID)," which found that early treatment with antiretroviral drugs (ARVs) reduced the risk of transmission among sero-discordant partners by 96 percent, as the "2011 Breakthrough of the Year," an NIH press release states (12/22). "Given resource constraints and logistical hurdles, treatment as prevention isn't going to sweep the world anytime soon," Science writes, adding, "But HPTN 052 has made imaginations race about the what-ifs like never before, spotlighting the scientifically probable rather than the possible" (Cohen, 12/23).

"The breakthrough was described by some experts as a tipping point in the fight against AIDS, 30 years after the epidemic first surfaced," Agence France-Presse writes, noting, "The annual top 10 list by the American Association for the Advancement of Science, which publishes the journal Science, appear[s] in the magazine's December 23 issue" (12/22). Xinhua describes the "nine other ground-breaking scientific achievements" on Science's list (12/23).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Study shows safety of kidney transplants among those with HIV infections